Hetero Ring Patents (Class 544/207)
-
Patent number: 11851417Abstract: Provided are solid forms of a compound useful for treating cancer, pharmaceutical compositions thereof, and methods of treating cancer comprising administering the solid forms described herein to a patient in need thereof.Type: GrantFiled: April 19, 2022Date of Patent: December 26, 2023Assignee: Servier Pharmaceuticals LLCInventors: Benjamin S. Lane, Chong-Hui Gu
-
Patent number: 9150701Abstract: The present invention relates to an UV absorbing polymer composition comprising effective amounts of (a1) a nanoparticulate oxide selected from oxides of the groups 4 and 12 of the periodic table, wherein the oxide is doped with In, Ga and/or Al, and (b1) a UV stabilizing/absorbing substance comprising a sterically hindered amine and/or a polymeric hydroxyphenyltriazine; or (a2) a nanoparticulate oxide selected from oxides of the groups 4 and 12, and (b2) a UV light stabilizing substance comprising a N-oxygen-substituted sterically hindered amine. Furthermore, the present invention relates to a polymer comprising said composition and the use of said composition as a UV absorber in polymers, particularly in agricultural films or packaging films. Finally, the present invention relates to a process for producing doped nanoparticulate metal oxides.Type: GrantFiled: December 12, 2008Date of Patent: October 6, 2015Assignee: BASF SEInventors: Mara Destro, Samanta Cimitan, Cesare Lorenzetti, Dario Lazzari
-
Patent number: 9006228Abstract: Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included.Type: GrantFiled: June 11, 2012Date of Patent: April 14, 2015Assignee: Merck Sharp & Dohme Corp.Inventors: Michael Miller, Andrew Stamford, Kallol Basu, Harold B. Wood, Duane DeMong, Wanying Sun, Joie Garfunkle, Christopher Moyes, Zhiyong Hu, Ping Liu, Scott D. Edmondson, Xing Dai, Byron Gabriel DuBois
-
Publication number: 20150038460Abstract: The invention relates to novel compounds of Formula I: wherein A, Y, R1, R2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.Type: ApplicationFiled: October 16, 2014Publication date: February 5, 2015Applicant: Genentech, Inc.Inventors: Steven Staben, Jianwen Feng, Pui Leng Loke, Christian A.G.N. Montalbetti
-
Publication number: 20150018328Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.Type: ApplicationFiled: July 11, 2014Publication date: January 15, 2015Applicant: AGIOS PHARMACEUTICALS, INCInventors: Zenon D. Konteatis, Janeta Popovici-Muller, Jeremy Travins, Robert Zahler, Zhenwei Cai, Ding Zhou
-
Publication number: 20140341986Abstract: Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.Type: ApplicationFiled: August 4, 2014Publication date: November 20, 2014Inventors: Alain D. Baron, Mark S. Fineman, Nigel R.A. Beeley
-
Publication number: 20140161845Abstract: The present invention provides non-peptide compounds of formula (I) wherein: X is —(C1-C8)allcyl-, aryl or -aryl(C1-C8)alkyl-; Y is —(C1-C8)alkyl- or absent; W is heteroaryl, (C3-C7)carbocycle or aryl, wherein any heteroaryl, (C3-C7)carbocycle or, aryl of W is optionally substituted with one or more (e.g. 1, 2, 3, 4 or 5) Z1 groups; R1 is (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl or aryl, wherein aryl is optionally substituted with one or more (e.g. 1, 2, 3, 4 or 5) groups selected from (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, halo(C1-C3)alkyl, —CN, NO2, halogen, —ORa, —SRa, —S(O)2NRbRc, —NRbRc, —NRaCORd, —C(O)Ra, —C(O)ORa, and —C(O)NRbRc; R2 is (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)Jalkynyl or aryl, wherein aryl is optionally substituted with one or more (e.g.Type: ApplicationFiled: July 20, 2012Publication date: June 12, 2014Applicant: University of Louisville Research Foundation Inc.Inventors: Donald R. Demuth, Frederick A. Luzzio
-
Patent number: 8742003Abstract: The present invention relates to silylated amino resins, to processes for preparing them, to their use, and to coating compositions comprising them.Type: GrantFiled: July 13, 2012Date of Patent: June 3, 2014Assignee: BASF SEInventors: Christina Haaf, Markus Hickl, Ruediger Stark, Horst Hintze-Bruening, Bernd Bruchmann, Dirk Schmelter, Thomas Gloege, Christine Roesch
-
Publication number: 20140113900Abstract: The present application relates to novel substituted imidazopyridazines, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases and to their use for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.Type: ApplicationFiled: May 2, 2012Publication date: April 24, 2014Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Markus Follmann, Johannes-Peter Stasch, Gorden Redlich, Alexander Straub, Jens Ackerstaff, Nils Griebenow, Andreas Knorr, Frank Wunder, Volkhart Min-Jian Li
-
Publication number: 20140088080Abstract: [Problem] An excellent drug for treating or preventing cardiovascular diseases, based on cGMP production enhancing action due to soluble guanylate cyclase activating action, is provided. [Means for Solution] It was found that imidazopyridine compounds having a carbamoyl group at the 3-position and a substituent bonded at the 8-position via an oxygen atom in an imidazo[1,2-a]pyridine skeleton exhibits a cGMP production enhancing action by a potent soluble guanylate cyclase activating action, and is useful as a drug for treating or preventing various soluble guanylate cyclase-related cardiovascular diseases, thereby completing the present invention.Type: ApplicationFiled: November 26, 2013Publication date: March 27, 2014Applicant: ASTELLAS PHARMA INC.Inventors: Yuji KOGA, Kyoichi MAENO, Ippei SATO, Yoshimasa IMAMURA, Takeshi HANAZAWA, Maiko IIDA, Kazuhiko OHNE, Kenichiro IMAMURA, Tsubasa WATANABE, Eisuke NOZAWA, Hiroshi SHIBATA
-
Patent number: 8657947Abstract: The present invention relates to silylated amino resins, to processes for preparing them, to their use, and to coating compositions comprising them.Type: GrantFiled: September 10, 2012Date of Patent: February 25, 2014Assignee: BASF SEInventors: Bastian Noller, Reinhold Schwalm, Christine Roesch, Thomas Breiner, Jean-Francois Stumbe, Christina Haaf
-
Publication number: 20140051676Abstract: The invention relates to new derivatives of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of chronic pain.Type: ApplicationFiled: October 15, 2013Publication date: February 20, 2014Applicant: NOVARTIS AGInventors: Oliver BARKER, Jonathan Mark BENTLY, Mark Gary BOCK, Thomas CAIN, Praful CHOVATIA, Jennifer Ruth DOD, Florence EUSTACHE, Laura GLEAVE, Jonathan HARGRAVE, Alexander HEIFETZ, Richard LAW, Ali RAOOF, David WILLOWS
-
Publication number: 20130178475Abstract: Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.Type: ApplicationFiled: March 10, 2011Publication date: July 11, 2013Applicant: IRONWOOD PHARMACEUTICALS, INC.Inventors: Joel Moore, James Jia, Takashi Nakai, Charles Kim, Thomas Wai-Ho Lee, Jane Yang
-
Patent number: 8455252Abstract: Disclosed herein are materials and methods for sensitizing multidrug resistant cancer cells that express ABCG2 and related proteins members of a family of ATP-binding transporter superfamily that mediate drug efflux found in some types of multidrug resistant cancer cells. A series of compounds, including (N-(4-chlorophenyl)-2-[(6-{[4,6-di(4-morpholinyl)-1,3,5-tri-azin-2-yl]amino}-1,3-benzothiazol-2-yl)sulfanyl]acetamide), specifically inhibits ABCG2 and can be used to boost the bio-avail-ability of one or more effective cancer killing drugs, making it possible to use certain widely used chemotherapeutic reagent to treat multidrug resistance cancers. Using these compounds in combination with chemotherapeutic drugs that are substrates for ABCG2 and related proteins may also find utility in treating cancer cells that are not currently identified as multi-drug resistant. Additionally, these compounds appear to accelerate the intercellular degradation of ABCG2 and related proteins.Type: GrantFiled: October 24, 2009Date of Patent: June 4, 2013Assignee: Indiana University Research and Technology Corp.Inventors: Jian-Ting Zhang, Jing Qi, Hui Peng, Zizheng Dong
-
Publication number: 20130095140Abstract: Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.Type: ApplicationFiled: July 11, 2012Publication date: April 18, 2013Applicant: Elcelyx Therapeutics, Inc.Inventors: Alain D. Baron, Mark S. Fineman, Nigel R. A. Beeley
-
Publication number: 20130059855Abstract: Provided are crystals of compound A which have properties suitable for industrial production. MEANS FOR SOLVING As the results of intensive studies to provide crystals of compound A having an inhibitory activity on the kinase activity of an EML4-ALK fusion protein and a mutant EGFR protein, crystals of compound A were found. Moreover, it was found that A04-type crystal of compound A, from among the aforesaid crystals of compound A, unexpectedly have preferred properties as a drug substance.Type: ApplicationFiled: May 16, 2011Publication date: March 7, 2013Applicant: ASTELLAS PHARMA INC.Inventors: Itsuro Shimada, Yutaka Hirakura, Kouji Yamazaki, Kazuhiro Takeguchi, Norihiro Ueda
-
Publication number: 20130023497Abstract: The present invention comprises inter alia triazine compounds as shown in formula (I) and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: June 7, 2010Publication date: January 24, 2013Inventors: Chunlin Tao, Qinwei Wang, Tulay Polat, Laxman Nallan, Neil Desai
-
Publication number: 20130000516Abstract: The present invention relates to silylated amino resins, to processes for preparing them, to their use, and to coating compositions comprising them.Type: ApplicationFiled: September 10, 2012Publication date: January 3, 2013Applicant: BASF SEInventors: Bastian Noller, Reinhold Schwalm, Christine Rösch, Thomas Breiner, Jean-Francois Stumbe, Cristina Haaf
-
Publication number: 20120330010Abstract: The present invention deals with a novel aromatic di-isoimide chemical compound that has utility as a catalyst and as a curing agent in epoxy compositions. The di-isoimide serves effectively as a thermally activated latent catalyst in epoxy curing, thereby increasing shelf life, and avoids premature cross-linking. Novel laminated articles and printed wiring boards, including encapsulated printed wiring boards are also disclosed. The composition hereof also can be used as a flame retardant in thermoplastic and thermoset polymers.Type: ApplicationFiled: June 24, 2011Publication date: December 27, 2012Applicant: E.I. DU PONT DE NEMOURS AND COMPANYInventor: GEORGE ELIAS ZAHR
-
Patent number: 8262945Abstract: Photochromic compositions are disclosed comprising a polymeric material, a photochromic dye, a hydroxyphenyl triazine UV absorber and, optionally, a further light stabilizer selected from the sterically hindered amines. These systems provide a reversible photochromic effect and show improved light stabilization and color fastness.Type: GrantFiled: July 24, 2009Date of Patent: September 11, 2012Assignee: BASF SEInventors: Mara Destro, Dario Lazzari, Dirk Simon, Manuele Vitali
-
Publication number: 20120214762Abstract: The invention relates to novel compounds of Formula I: wherein A, Y, R1, R2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.Type: ApplicationFiled: March 15, 2012Publication date: August 23, 2012Applicant: Genentech, Inc.Inventors: Steven Staben, Jianwen Feng, Pui Leng Loke, Christian A.G.N. Montalbetti
-
Publication number: 20120184557Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, where R1 is a (C1-C6)alkyl or (C3-C6)cycloalkyl group; R2 is a (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkenyl, (C1-C6)fluoroalkyl, (C1-C3)fluoroalkoxy, or (C1-C6)alkoxy(C1-C6)alkyl group, substituted: (i) with one to three hydroxyl groups, or (ii) with an NRaRb group, where Ra and Rb are independently a hydrogen atom or a (C1-C3)alkyl group; or a pyrrolidinylmethyl group substituted with one to three hydroxyl groups; R9 is the same as R2 or hydrogen; the R2 and R9 groups independently being substitutable with an —OCOR3 group, where R3 is a natural or unnatural amino acid derivative or a piperidyl group; alternatively, R2 and R9 together form a heterocyclic compound; X and Y are independently a substitutable phenyl or heteroaryl group, the heteroaryl group being a thienyl, pyridyl, pyrimidinyl, thiazolyl, pyrrolyl, or furanyl group; and R6 is a hydrogen or a (C1-C3)alkyl group.Type: ApplicationFiled: March 11, 2010Publication date: July 19, 2012Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE CLAUDE BERNARD LYON 1, UNIVERSITE PARIS DESCARTESInventors: Laurent Meijer, Hervé Galons, Benoit Joseph, Florence Popowycz, Nassima Oumata
-
Publication number: 20120059000Abstract: Chemical compounds that modulate kinase activity, including PI3 kinase activity, and chemical compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein.Type: ApplicationFiled: May 20, 2011Publication date: March 8, 2012Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Alfredo C. Castro, Catherine A. Evans
-
Patent number: 7858626Abstract: Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.Type: GrantFiled: July 30, 2007Date of Patent: December 28, 2010Assignee: GlaxoSmithKline LLCInventors: Amogh Boloor, Mui Cheung, Ronda Gayle Davis-Ward, Philip Anthony Harris, Kevin Hinkle, Christopher P. Lauderman, Robert Anthony Mook, Jr., Jeffery Alan Stafford, James Marvin Veal
-
Publication number: 20100305317Abstract: Synthesis of biguanidines and triazines, and biguanidino-aluminium complexes as intermediates Compounds of formula (I) or salts thereof, in which R1, R2, R3, R4, R5, R6, X and Y are defined as in claim 1, can be prepared by a process characterized in that a compound of the formula (II) or a salt thereof, is reacted to a compound of the formula (III) or a salt thereof, and an aluminium (III) source, optionally, in the presence of a protic additive or solvent selected from the group consisting of alcohols or amines. The compounds (I) are suitable to be used for the preparation of heterocyclic compounds corresponding to (I) where the group Al(X)(Y) is replaced with an optionally substituted carbon atom, or s-triazine derivatives thereof.Type: ApplicationFiled: November 25, 2008Publication date: December 2, 2010Applicant: Bayer CropScience AGInventor: Mark James Ford
-
Patent number: 7834014Abstract: The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula (I).Type: GrantFiled: April 9, 2004Date of Patent: November 16, 2010Assignee: Biogen Idec MA Inc.Inventors: Hairuo Peng, Gang Yao, Russell C. Petter, Gnanasambandam Kumaravel
-
Publication number: 20100222342Abstract: Pyrrole pyrazole compounds of formula I, compositions including these compounds and methods of their use are provided. Preferred compounds of formula I have activity as protein kinase inhibitors, including as inhibitors of PAK4.Type: ApplicationFiled: December 28, 2005Publication date: September 2, 2010Inventors: Junhu Zhang, Chuangxing Guo, Djamal Bouzida, Liming Dong, Haitao Li, Joseph Timothy Marakovits, Anle Yang, Yufeng Hong
-
Publication number: 20100210656Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R4, R5, R6, A, B, Y, Z, n, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.Type: ApplicationFiled: October 10, 2008Publication date: August 19, 2010Inventors: Yun Ding, Reema K. Thalji, Joseph P. Marino, JR.
-
Publication number: 20100127616Abstract: Disclosed is an organic electroluminescent device (organic EL device) which is improved in luminous efficiency, fully secured of driving stability, and of simple constitution. Also disclosed is a compound useful for the fabrication of said organic EL device. The organic electroluminescent device comprises organic layers including a light-emitting layer disposed between an anode and a cathode which are piled one upon another on a substrate and at least one of said organic layers comprises a compound for an organic EL device represented by general formula (1). Said organic layer is preferably a light-emitting layer containing a phosphorescent dopant.Type: ApplicationFiled: March 26, 2008Publication date: May 27, 2010Applicant: NIPPON STEEL CHEMICAL CO., LTD.Inventors: Takahiro Kai, Toshihiro Yamamoto, Masanori Hotta, Junya Ogawa
-
Patent number: 7723335Abstract: A compound of the formula (I) wherein each Z is the same or different and is formula (a) or —Y wherein each X is the same or different and is a multivalent aminyl group or diaminyl-terminated spacer; each Y is the same or different aminyl group; and M is a support matrix.Type: GrantFiled: December 9, 2003Date of Patent: May 25, 2010Assignee: Prometic Biosciences Ltd.Inventors: Steven James Burton, Abid Hussain, James Christopher Pearson
-
Patent number: 7683061Abstract: Compounds containing two mono- or disubstituted triazine rings covalently linked by an organic linker, but not linked directly to each other, may be used to treat autoimmune diseases. Autoimmune diseases which are amenable to treatment with compounds of this invention include rheumatoid arthritis, systemic lupus erythematosus (SLE), idiopathic (immune) thrombocytopenia (ITP), glomerulonephritis and vasculitis. The present invention also relates to reducing drug toxicity which often accompanies traditional therapies for autoimmune diseases. The compounds may also be used to bind antibody in vitro or ex vivo.Type: GrantFiled: November 22, 2004Date of Patent: March 23, 2010Assignee: ProMetic BioSciences Inc.Inventors: Christopher Penney, Boulos Zacharie, Shaun D. Abbott, Jean-François Bienvenu, Alan D. Cameron, Jean-Simon Duceppe, Abdallah Ezzitouni, Daniel Fortin, Karine Houde, Nancie Moreau, Nicole Wilb, Brigitte Grouix, Lyne Gagnon
-
Publication number: 20100044695Abstract: Disclosed is an organic electroluminescent device (organic EL device) which is improved in luminous efficiency, fully secured of driving stability, and of simple constitution. Also disclosed is a compound useful for the fabrication of said organic EL device. The organic electroluminescent device comprises organic layers including a light-emitting layer disposed between an anode and a cathode which are piled one upon another on a substrate and said organic layers comprise a compound represented by general formula (1). A light-emitting layer containing a phosphorescent dopant is suitable for an organic layer comprising a compound represented by general formula (1).Type: ApplicationFiled: March 24, 2008Publication date: February 25, 2010Applicant: Nippon Steel Chemical Co., Ltd.Inventors: Takahiro Kai, Toshihiro Yamamoto, Masanori Hotta, Junya Ogawa
-
Patent number: 7608620Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-? activity.Type: GrantFiled: November 16, 2006Date of Patent: October 27, 2009Assignee: Cell Therapeutics, Inc.Inventors: Lynn Bonham, Baoqing Gong, Robert E Finney, David M Hollenback, J Peter Klein, David W Leung, Scott A Shaffer, Norina M Tang, John Tulinsky, Thayer H White
-
Patent number: 7592451Abstract: The present invention relates to a compound having the formula where Z is an amine, phenoxy, or thiol-containing group, and Y is an alkyl-containing amine. Methods of producing such compounds and using them to treat patients with diabetes and obesity are also disclosed. The present invention also relates to treating such conditions with GADPH inhibitors and screening compounds useful for treating such conditions by using GADPH inhibitors. Compounds can also be screened for their effectiveness in modulating diabetes and obesity with a C. elegans strain.Type: GrantFiled: June 20, 2006Date of Patent: September 22, 2009Assignee: New York UniversityInventors: Young-Tae Chang, Fabio Piano
-
Patent number: 7563792Abstract: Biguanide and dihydrotriazine derivatives, preferably substituted asymmetrical imidodicarbonimidic diamides derived from hydroxylamines, and compositions containing biguanide and dihydrotriazine derivatives are disclosed. In addition, methods of using the biguanide and dihydrotriazine derivatives, inter alia, as antimicrobial agents and methods of using the dihydrotriazine derivatives in biological assays are disclosed. Methods of making the biguanide and dihydrotriazine derivatives are also disclosed.Type: GrantFiled: June 27, 2007Date of Patent: July 21, 2009Assignee: Jacobus Pharmaceutical Company, Inc.Inventors: David P. Jacobus, Guy A. Schiehser, Hong-Ming Shieh, Norman P. Jensen, Jacek Terpinski
-
Publication number: 20090142347Abstract: This invention relates generally to the field of mineralization, and specifically to the role of TNAP in regulating the levels of extracellular inorganic pyrophosphate. The invention provides methods for modulating the activity of TNAP activity; methods for screening for modulators of TNAP activity; modulators of TNAP activity; and methods for treating pathologic conditions known of suspected to be affected by modulation of TNAP activity.Type: ApplicationFiled: September 29, 2005Publication date: June 4, 2009Applicant: THE BURNHAM INSTITUTE FOR MEDICAL RESEARCHInventor: José Luis Millan
-
Publication number: 20090008002Abstract: A novel compound, used for example, as a gas generating fuel, is defined as a compound having the structural formula of wherein: R4 is a triazine ring; R1 is selected from the group consisting of a tetrazolyl group, CH3, OCH3, —CN, —C2H, NCO, —NHNH2, NO, NO2, OH, Cl, —NHCONH2, —OCOR, NHNO2, substituted tetrazoles, and substituted triazoles; R2 is selected from the group consisting of a tetrazolyl group, CH3, OCH3, —CN, —C2H, NCO, —NHNH2, NO, NO2, OH, Cl, —NHCONH2, —OCOR, NHNO2, substituted tetrazoles, and substituted triazoles; R3 is selected from the group consisting of a tetrazolyl group, CH3, OCH3, —CN, —C2H, NCO, —NHNH2, NO, NO2, OH, Cl, —NHCONH2, —OCOR, NHNO2, substituted tetrazoles, and substituted triazoles.Type: ApplicationFiled: October 1, 2007Publication date: January 8, 2009Inventors: Sudhakar R. Ganta, Cory G. Miller, Graylon K. Williams
-
Patent number: 7449575Abstract: This invention concerns the compounds of formula the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein R1 and R2 are each independently selected from hydrogen; hydroxy; amino; optionally substituted C1-6alkyl; C1-6alkyloxy; C1-6alkylcarbonyl; C1-6alkyloxycarbonyl; Ar1; mono- or di(C1-6alkyl)amino; mono- or di(C1-6alkyl)-aminocarbonyl; dihydro-2(3H)-furanone; or R1 and R2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C1-6alkyl)amino-C1-4alkylidene; R3 is hydrogen, Ar1, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxy-carbonyl, C1-6alkyl substituted with C1-6alkyloxycarbonyl; and R4, R5, R6, R7 and R8 are each independently selected from hydrogen, halo, C1-6alkyl, C1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl or trihalomethyloxy; L is optionally substituted C1-10alkyl; C3-10alkenyl; C3-10alkynyl; C3-7cycloalkyl; Ar1 is optionally substituted phenyl; for the manufacture of a medicine for the treatment ofType: GrantFiled: August 12, 2005Date of Patent: November 11, 2008Assignee: Janssen Pharmaceutica, Inc.Inventors: Paul A. J. Janssen, Jan Heeres, Henri E. L. Moereels, Michael Joseph Kukla, Donald W. Ludovici
-
Publication number: 20080176853Abstract: The invention provides for Triazine derivatives and their use to modulate protein kinase activity in a variety of conditions and diseases.Type: ApplicationFiled: December 14, 2007Publication date: July 24, 2008Applicant: Abraxis BioScience, Inc.Inventors: Chunlin Tao, Qinwei Wang, Neil P. Desai, Patrick Soon-Shiong
-
Patent number: 7354921Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]triazine compounds as inhibitors of kinases such as, for example, cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the kinases using such compounds or pharmaceutical compositions.Type: GrantFiled: October 12, 2006Date of Patent: April 8, 2008Assignee: Schering CorporationInventors: Timothy J. Guzi, Kamil Paruch
-
Patent number: 7335770Abstract: The present invention relates to triazine compounds and their analogs and derivatives, and methods and compositions comprising these compounds. The compounds and compositions of this invention are useful for, among other things, treating pathophysiological conditions arising from inflammatory responses, inhibiting or blocking glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells, inhibiting smooth muscle proliferation, treating vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis, and the like.Type: GrantFiled: March 24, 2004Date of Patent: February 26, 2008Assignee: Reddy U5 Therapeutics, Inc.Inventors: Richard T. Timmer, Christopher W. Alexander, Sivaram Pillarisetti, Uday Saxena, Sesha Sridevi Alluri, Velagala Venkata Rama Murali Krishna Reddy, Manojit Pal, Jangalgar Tirupathy Reddy, Koteswar Rao Yeleswarapu, Gaddam Om Reddy, Potlapally Rajender Kumar
-
Patent number: 7332490Abstract: The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.Type: GrantFiled: May 25, 2006Date of Patent: February 19, 2008Assignee: Reddy US Therapeutics, Inc.Inventors: Richard T. Timmer, Christopher W. Alexander, Sivaram Pillarisetti, Uday Saxena, Koteswar Rao Yeleswarapu, Manojit Pal, Jangalgar Tirupathy Reddy, Velagala Venkata Rama Murali Krishna Reddy, Sesha Sridevi Alluri, Potlapally Rajender Kumar, Gaddam Om Reddy
-
Patent number: 7332488Abstract: The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.Type: GrantFiled: August 28, 2006Date of Patent: February 19, 2008Assignee: Reddy US Therapeutics, Inc.Inventors: Richard T. Timmer, Christopher W. Alexander, Sivaram Pillarisetti, Uday Saxena, Koteswar Rao Yeleswarapu, Manojit Pal, Jangalgar Tirupathy Reddy, Velagala Venkata Rama Murali Krishna Reddy, Sesha Sridevi Alluri, Potlapally Rajender Kumar, Gaddam Om Reddy
-
Publication number: 20070293399Abstract: The invention relates to a compound of the formula (I) or a salt thereof in which R1 is a radical of the formula —N(B1-D1)(B2-D2) or —N(B3-D3)-N(B4-D4) (B5-D5), or a group of the formula where B1, B2, B3, B4, B5, D1, D2, D3, D4, D5, G1, L1, U1, U2, U3, and U4 are each as defined in the specification are suitable as herbicides and crop growth regulators. The compounds (I) can be prepared by processes described in the specification, via intermediates including novel intermediates.Type: ApplicationFiled: April 11, 2007Publication date: December 20, 2007Applicant: Bayer CropScience AGInventors: Klemens Minn, Hansjorg Dietrich, Thomas Auler, Martin Hills, Heinz Kehne, Dieter Feucht
-
Patent number: 7307079Abstract: The invention relates to a group of novel triazine derivatives which are ligands for human adenosine-A3 receptors, as well as to pharmaceutical compositions containing a pharmacologically active amount of at least one of these compounds as an active ingredient. The invention relates to compounds of the general formula (1) wherein Y represents a group of the general formula (A), (B) or (C) and all other symbols have the meanings as given in the description.Type: GrantFiled: May 30, 2003Date of Patent: December 11, 2007Assignees: Solvay Pharmaceuticals, B.V., Arqule, Inc.Inventors: Jacobus A.J. Den Hartog, Jan H. Reinders, Guustaaf J.M. Van Scharrenburg, Maria L. Pras-Raves, Gary R. Gustafson
-
Patent number: 7285550Abstract: The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease.Type: GrantFiled: April 9, 2004Date of Patent: October 23, 2007Assignee: Biogen Idec MA Inc.Inventors: Chi Vu, Russell C. Petter, Gnanasambandam Kumaravel
-
Patent number: 7265114Abstract: The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.Type: GrantFiled: November 22, 2005Date of Patent: September 4, 2007Assignee: Reddy US Therapeutics, Inc.Inventors: Richard T. Timmer, Christopher W. Alexander, Sivaram Pillarisetti, Uday Saxena, Yeleswarapu Koteswar Rao, Manojit Pal, Jangalgar Tirupathy Reddy, Velagala Venkata Rama Murali Krishna Reddy, Sesha Sridevi Alluri, Potlapally Rajender Kumar, Gaddam Om Reddy
-
Patent number: 7205298Abstract: The present invention provides substituted 1,3,5-triazine compounds as kinase inhibitors and a method for treating or ameliorating a kinase mediated disorder.Type: GrantFiled: July 18, 2003Date of Patent: April 17, 2007Assignee: Janssen Pharmaceutica N.V.Inventors: Gee-Hong Kuo, Alan DeAngelis, Aihua Wang, Yan Zhang, Stuart L. Emanuel, Steve Middleton
-
Patent number: 7173032Abstract: The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.Type: GrantFiled: March 17, 2003Date of Patent: February 6, 2007Assignee: Reddy US Therapeutics, Inc.Inventors: Richard T. Timmer, Christopher W. Alexander, Sivaram Pillarisetti, Uday Saxena, Karen A. Campbell
-
Patent number: 7169785Abstract: The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.Type: GrantFiled: March 26, 2003Date of Patent: January 30, 2007Assignee: Reddy US Therapeutics, Inc.Inventors: Richard T. Timmer, Christopher W. Alexander, Sivaram Pillarisetti, Uday Saxena, Koteswar Rao Yeleswarapu, Manojit Pal, Jangalgar Tirupathy Reddy, Velagala Venkata Rama Murali Krishma Reddy, Sesha Sridevi Alluri, Potlapally Rajender Kumar, Gaddam Om Reddy